POINT Biopharma Global (Nasdaq:PNT) - Aktienkurs, Nachrichten und Analyse

PNT Aktienübersicht

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer.

PNT fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Belohnungen

71.5% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 9.19% pro Jahr

In diesem Jahr profitabel geworden

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Stark schwankender Aktienkurs in den letzten 3 Monaten

POINT Biopharma Global Inc. Wettbewerber

TG Therapeutics

NasdaqCM:TGTX

US$2.4b

Entrada Therapeutics

NasdaqGM:TRDA

US$501.1m

Kiniksa Pharmaceuticals

NasdaqGS:KNSA

US$1.3b

Krystal Biotech

NasdaqGS:KRYS

US$5.1b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for POINT Biopharma Global
Historical stock prices
Current Share Price	US$12.50
52 Week High	US$14.35
52 Week Low	US$6.57
Beta	-0.0026
1 Month Change	-9.49%
3 Month Change	87.41%
1 Year Change	75.07%
3 Year Change	-10.20%
5 Year Change	n/a
Change since IPO	3.99%

Aktuelle Nachrichten und Updates

Recent updates

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

Aug 20

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

Aktionärsrenditen

	PNT	US Biotechs	US Markt
7D	0.2%	0.1%	1.2%
1Y	75.1%	7.1%	20.8%

Rendite im Vergleich zur Industrie: PNT übertraf die Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: PNT übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is PNT's price volatile compared to industry and market?
PNT volatility
PNT Average Weekly Movement	24.6%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: PNTDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: PNTDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 13% auf 25% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2019	129	Joe McCann	www.pointbiopharma.com

POINT Biopharma Global Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von POINT Biopharma Global im Vergleich zum Marktanteil des Unternehmens?
PNT grundlegende Statistiken
Marktanteil	US$1.33b
Gewinn(TTM)	US$96.55m
Umsatz(TTM)	US$243.69m

13.8x

Kurs-Gewinn-Verhältnis

5.5x

Kurs-Umsatz-Verhältnis

Ist PNT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
PNT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$243.69m
Kosten der Einnahmen	US$0
Bruttogewinn	US$243.69m
Sonstige Ausgaben	US$147.14m
Umsatz	US$96.55m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.91
Bruttomarge	100.00%
Nettogewinnspanne	39.62%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich PNT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

PNT Aktienübersicht

Belohnungen

Risikoanalyse

POINT Biopharma Global Inc. Wettbewerber

NasdaqCM:TGTX

US$2.4b

NasdaqGM:TRDA

US$501.1m

NasdaqGS:KNSA

US$1.3b

NasdaqGS:KRYS

US$5.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

Price target decreased by 19% to US$13.85

Recent updates

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

Price target decreased by 19% to US$13.85

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 24%

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

New major risk - Share price stability

Price target decreased by 9.2% to US$15.44

Investor sentiment improves as stock rises 81%

Consensus revenue estimates fall by 54%

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

High number of new directors

POINT Biopharma Global Inc. Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress

Point Biopharma Global Inc. Appoints Bridget Martell to Its Board of Directors

Consensus EPS estimates upgraded to US$0.80 loss

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

Price target increased by 7.3% to US$16.90

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 18%

Independent Director exercised options to buy US$122k worth of stock.

Forecast to breakeven in 2024

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial

POINT Biopharma Global Inc. Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Executive Chairman recently bought US$311k worth of stock

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to US$19.00

High number of new directors

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, A Next-Generation PSMA Ligand, At EANM's Annual Congress

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Point Biopharma plummets on announcing common stock offering

Price target increased to US$21.00

POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05

POINT Biopharma Announces Appointment of Chris Horvath as Executive Vice President, Commercial

Chief Medical Officer & Director recently sold US$4.2m worth of stock

POINT Biopharma Global Inc. Unveils FRONTIER: A Pan-Cancer Fap-A Targeted Clinical Program

POINT Biopharma Global Inc. Confirms No Supply Shortages of 177Lu-PNT2002 for the Splash Trial

High number of new and inexperienced directors

POINT Biopharma Global Announces First Patient in European Union (EU) Dosed in the Phase 3 Splash Trial

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH Trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

POINT Biopharma Global Inc., Annual General Meeting, Jun 02, 2022

High number of new and inexperienced directors

POINT Biopharma Global Inc. Releases New Data and Exercises Option for Best-In-Class FAP Inhibitor

POINT Biopharma Global Inc. Announces Initiation of Randomization for Its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of Its Phase 3 SPLASH Study of PNT2002 for mCRPC

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

POINT Biopharma Global Inc.'s Grundlagenzusammenfassung

13.8x

5.5x

Erträge &amp; Einnahmen

Erträge & Einnahmen